In this issue:
Guselkumab elicits rapid and durable improvements in axial disease
Little impact of COVID pandemic on medication use in patients with rheumatic diseases
COVID mRNA vaccines safe and immunogenic in patients with IRD undergoing immunosuppressive therapy
Most patients with IRD mount a humoral response to Pfizer COVID vaccine
Two-dose Pfizer COVID vaccine immunogenic but rituximab reduces humoral response
Extraarticular pain is widespread in PsA and impacts clinical outcomes
Maternal psoriatic disease impacts maternal but not neonatal outcomes
Quality of physician-patient communication impacts quality of life
Secukinumab reduces structural damage progression regardless of rate of progression
PROs comparable with adalimumab biosimilar SDZ-ADL versus originator in PsA, Ps and RA
Please login below to download this issue (PDF)